Piramal Pharma Financial Results
- Market cap
- ₹26,843 crore
- P/E
- 22.5
- P/B
- 3.29
- ROE
- -4.0%
- Dividend yield
- 1.20%
For the year ended Mar 2023, Piramal Pharma reported revenue of ₹7,032 crore and net profit of -₹186 crore, against ₹8,106 crore and ₹18 crore a year earlier.
Piramal Pharma annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | 7,032 | 8,106 | 9,061 | 8,759 | 9,095 |
| Expenses | 6,404 | 6,904 | 7,566 | 7,773 | 8,020 |
| Operating profit | 629 | 1,203 | 1,495 | 986 | 1,075 |
| Operating margin % | 9% | 15% | 16% | 11% | 12% |
| Other income | 266 | 164 | 154 | 7 | 19 |
| Interest | 338 | 447 | 418 | 338 | 340 |
| Depreciation | 677 | 741 | 816 | 831 | 858 |
| Profit before tax | -120 | 179 | 415 | -176 | -104 |
| Tax % | -55% | 90% | 78% | -85% | -200% |
| Net profit | -186 | 18 | 91 | -326 | -314 |
| EPS (₹) | -1.53 | 0.14 | 0.69 | -2.46 | -2.37 |
| Dividend payout % | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Piramal Pharma financial results — frequently asked questions
What is Piramal Pharma's annual revenue and net profit?
For the financial year ended Mar 2023, Piramal Pharma's revenue was ₹7,032 crore and net profit -₹186 crore; net profit fell 1,133.33% from ₹18 crore in Mar 2024.
How fast has Piramal Pharma grown over three years?
From Mar 2026 to Mar 2023, Piramal Pharma's revenue grew at a compound annual rate of -7.1%. Past growth does not indicate future results.
What is the EPS of Piramal Pharma?
Annual EPS for Mar 2023 was -₹1.53.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Piramal Pharma With ATS
Track PPLPHARMA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.